Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema

Short-Term Outcomes of Intravitreal Faricimab Injection for Diabetic Macular Edema

<i>Background and Objectives</i>: Faricimab is a novel bispecific antibody with Fab regions inhibiting both vascular endothelial growth factor-A and angiopoietin-2. Therefore, this study aimed to obtain short-term outcomes of intravitreal injection of faricimab (IVF) for the treatment of...

Full description

Bibliographic Details
Main Authors: Sentaro Kusuhara, Maya Kishimoto-Kishi, Wataru Matsumiya, Akiko Miki, Hisanori Imai, Makoto Nakamura
Format: Article
Language:English
Published: MDPI AG 2023-03-01
Series:Medicina
Subjects:
diabetic macular edema
vascular endothelial growth factor
angiopoietin
faricimab
visual acuity
retinal thickness
Online Access:https://www.mdpi.com/1648-9144/59/4/665

Internet

https://www.mdpi.com/1648-9144/59/4/665

Similar Items